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1578Successful Stem Cell Remobilization Using Plerixafor
(Mozobil) Plus Granulocyte Colony-Stimulating Factor
in Patients with Non-Hodgkin Lymphoma: Results from
the Plerixafor NHL Phase 3 Study Rescue Protocol
Ivana N. Micallef,1 Patrick J. Stiff,2 John F. DiPersio,3 Richard T. Maziarz,4 John M. McCarty,5
Gary Bridger,6 Gary Calandra6In a phase 3 multicenter, randomized, double-blinded, placebo-controlled study of 298 patients with non-
Hodgkin lymphoma (NHL), granulocyte colony-stimulating factor (G-CSF) plus plerixafor increased the pro-
portion of patients who mobilized $5  106 CD341 hematopoietic stem cells (HSCs)/kg compared with
placebo plus G-CSF (P\.001). Patients in either study arm who failed mobilization (\ 0.8  106 CD341
cells/kg in 2 collections or\2 106 CD341 cells/kg in 4 collections) were eligible to enter the opened-label
rescue protocol. Following a 7-day minimum rest period, these patients received G-CSF (10 mg/kg/day) for 4
days, followed by daily plerixafor (0.24 mg/kg) plus G-CSF and apheresis for up to 4 days. Of the 68 patients
failing initial mobilization (plerixafor, n5 11; placebo, n5 57), 62 patients (91%) entered the rescue proce-
dure (plerixafor, n5 10; placebo, n5 52). Four of 10 patients (40%) from the plerixafor group and 33 of 52
(63%) from the placebo group mobilized sufficient CD341 cells ($ 2 106 cells/kg) for transplantation from
the rescue mobilization alone (P5.11). Engraftment of neutrophils (11 days) and platelets (20 days) was sim-
ilar to that in patients who did not fail initial mobilization, and all patients had durable grafts at the 12-month
follow-up. Common plerixafor-related adverse events (AEs) included mild gastrointestinal (GI) effects and
injection site reactions. There were no drug-related serious AEs. These data support that plerixafor plus
G-CSF can safely and effectively remobilize patients with NHL who have failed previous mobilization.
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Between 11% and 53% of patients with non-
Hodgkin lymphoma (NHL) do not successfully mobi-
lize sufficient hematopoietic stem cells (HSCs) for
transplantation with either cytokines alone or in com-
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6/j.bbmt.2009.08.005patients undergo a repeat mobilization procedure,
usually within 2 weeks of the initial procedure. Early
remobilization has been associated with better
mobilization outcome and lower risk of disease pro-
gression and infection [4].
Conventionally, patients who fail cytokine-only
mobilization are treated with increasing doses of gran-
ulocyte colony-stimulating factor (G-CSF), G-CSF
plus another cytokine (eg, granulocyte monocyte
colony-stimulating factor [GM-CSF] or an investiga-
tional agent, such as hepatocyte growth factor or
stem cell factor), G-CSF plus chemotherapy, or
G-CSF plus an investigational agent. The success
rate with these regimens is typically only 20%-50%,
however [4,8-10]. Results of remobilization studies
are typically confounded by such factors as the lack
of a well-defined patient population with any strict in-
clusion/exclusion criteria and the lack of a consistent
definition of poor mobilization.
Plerixafor is a small-molecule bicyclam derivative
that blocks the interaction between the chemokine
receptor, CXCR4, and stromal cell-derived factor 1
(SDF-1) [11]. Plerixafor plus G-CSF has been shown
Day 1 Day 2 Day 3 4 5 6 Day 7 8
Mobilization Collec tion*Rest Period 
( 7 days) 
G-CSF (10 µg/kg/day)
Apheresis 
Plerixafor (0.24 mg/kg/day)
Mobilization failure (<0.8 × 106 cells in ≥2 days or <2.0 × 106 cells in 4 days)
*Collect ion continued for a maximum of 4 days, or until 5 × 106 cells were collected.
≥
Day Day Day Day 
Figure 1. Study design and treatment plan.
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withNHLormultiplemyeloma (MM)whowere found
to be poor mobilizers with a G-CSF regimen [2].
In a phase 2 study of 49 patients with NHL or MM,
28 patients were deemed to be heavily pretreated, as de-
fined by having previously received 10 ormore cycles of
chemotherapy, platinum-based chemotherapy, or irra-
diation to bone marrow (BM)-bearing sites [12]. Ad-
ministration of plerixafor plus G-CSF resulted in
a median fold increase in CD341 cell count that was
similar in the heavily pretreated and non-heavily pre-
treated patients. In addition, the median number of
aphereses, median yield of CD341 cells, and engraft-
ment of both neutrophils and platelets were similar in
the 2 groups, indicating that plerixafor plus G-CSF re-
sulted in successful mobilization even in the heavily
pretreated patients.
In a phase 3 randomized study comparing placebo
plus G-CSF with plerixafor plus G-CSF for CD341
HSC mobilization in patients with NHL, the mini-
mum cell yield for transplantation was defined as
$2 106 CD341 cells/kg within 4 aphereses [13]. Pa-
tients who achieved cumulative yields of\0.8  106
CD341 cells/kg after 2 days of apheresis or \2 
106 CD341 cells/kg after 4 days of apheresis were con-
sidered to have failed mobilization and were given the
option of entering an opened-label rescue protocol for
remobilization with plerixafor plus G-CSF. The
purpose of the present analysis was to assess whether
plerixafor plus G-CSF is a generally safe and effective
remobilization strategy for patients who have failed
a prior mobilization attempt with placebo plus
G-CSF or plerixafor plus G-CSF.METHODS
Study Design and Patients
Patients in the placebo or plerixafor arm of the ran-
domized phase 3 study [13] who were unable to collect
either a total of$0.8 106 CD341 cells/kg in 2 days of
apheresis or $2  106 CD341 cells/kg in 4 days ofapheresis had the option of entering an opened-label
rescue protocol, for which a separate informed consent
was obtained. Study staff and patients remained
blinded to the study treatment received before enter-
ing the rescue protocol.Study Treatment
Following a rest period of at least 7 days after the
initial mobilization attempt, patients were given
G-CSF (10 mg/kg/day) s.c. for 4 days (days 1-4). On
the evening of day 4, patients were given plerixafor
0.24 mg/kg s.c. On the morning of day 5, patients
were given G-CSF (10 mg/kg/day) s.c., followed by
apheresis. Apheresis was started approximately 10-11
hours after each dose of plerixafor. The patients con-
tinued to receive an evening dose of plerixafor fol-
lowed by G-CSF the next morning, before apheresis,
for up to a total of 4 aphereses or until $5  106
CD341 cells/kg were collected (Figure 1). The efficacy
of mobilization was assessed by the peripheral blood
(PB) CD341 cell count performed locally, as well as
by the yield of CD341 cells/kg collected by apheresis.Transplantation
After completion of HSC collection, patients un-
derwent myeloablative (MA) chemotherapy using the
same regimens as used in the parent phase 3 study, fol-
lowed by transplantation. All transplantations were
performed within 5 weeks of the last apheresis, accord-
ing to the standard of care at the study center. A min-
imum of $2  106 CD341 cells/kg (actual body
weight) were required for transplantation; transplanta-
tion with fewer than 2  106 cells/kg was permitted
only at the investigator’s discretion. In the event that
a sufficient number of cells for transplantation could
not be obtained from the collection, cells could be re-
tained to be pooled and transplanted at a later date at
the investigator’s discretion.
a Based on laboratory criteria. 
10 patients from plerixafor
arm entered rescue protocol
6 (60%) Yes 
52 patients from placebo arm 
entered rescue protocol
46 (88%) Yes
Proceeded to
transplant
Proceeded to
transplant
Patients with durable graft at 100 daysa
48 (97.3%) of 52 evaluable patients
Patients with durable graft at 6 monthsa
43 (93.5%) of 46 evaluable patients
Patients with durable graft at 12 monthsa
40 (90.9%) of 44 evaluable patients
4 No
(1 died, 1 refused transplant, 
2 failed mobilization).
6 No
(1 died, 1 “other”, 4 failed 
mobilization). 
Figure 2. Patient disposition.
1580 Biol Blood Marrow Transplant 15:1578-1586, 2009I. N. Micallef et al.Engraftment
Neutrophil engraftment was defined as neutrophil
count of $0.5  109/L for 3 consecutive days or
$1.0  109/L for 1 day. Platelet engraftment was de-
fined as platelet count of$20 109/L without a trans-
fusion during the preceding 7 days. Graft durability
was defined as maintenance of normal blood counts ac-
cording to at least 2 of the 3 following criteria: platelet
count .50  109/L without transfusion for at least
2 weeks before the follow-up visit, hemoglobin level
$10 g/dL with no erythropoietin support or transfu-
sions for at least 1 month before the follow-up visit,
and absolute neutrophil count (ANC) .1  109/L
with no G-CSF treatment for at least 1 week before
the follow-up visit. Graft durability was assessed by
the investigator at each study site. Patients who
achieved, but did not maintain, these blood counts be-
cause of other causes (eg, recurrent or progressive dis-
ease, renal failure, chronic bleeding, severe infection,
drug-induced cytopenia, development of new hemato-
logic problems) were considered to have durable
grafts.Safety
Safety was monitored by the incidence of adverse
events (AEs), serious adverse events (SAEs), and
changes from baseline in medical history, clinical
laboratory measurements (ie, chemistry, hematologyincluding complete blood count with differential, uri-
nalysis, and coagulation), vital sign parameters, and
physical examination findings. Safety issues arising
during the course of the study were evaluated
throughout by an independent Data Safety Monitor-
ing Board.Statistical Analysis
Descriptive statistics were used to summarize
CD341 cell collections, number of days of apheresis,
PB CD341 cell counts, and days to neutrophil and
platelet engraftment. Continuous data are presented
as mean, standard deviation, median, minimum, and
maximum for treatment assignment in the phase 3
study and overall. All analyses were performed using
SAS software (SAS Institute, Cary, NC) and Excel
software (Microsoft, Redmond, WA).RESULTS
Patients
In the parent phase 3 study, 150 patients with
NHL were randomized to the plerixafor group and
148 patients were randomized to the placebo group.
Eleven of the 150 patients in the plerixafor group
(7.3%) and 57 of the 148 patients in the placebo
group (38.5%) failed mobilization. Of these 68
Table 1. Patient Demographics and Baseline Characteristics: Medical, Surgery, and Oncology History
Plerixafor (n510) Placebo (n552) Total (n562)
Age, years, mean (SD) 54.6 (13.1) 59.9 (8.8) 59.0 (9.7)
Male, n (%) 7 (70.0%) 36 (69.2%) 43 (69.4%)
Ethnic origin, n (%)
Caucasian 9 (90.0%) 47 (90.4%) 56 (90.3%)
African-American 0 (0.0%) 1 (1.9%) 1 (1.6%)
Asian 1 (10.0%) 1 (1.9%) 2 (3.2%)
Hispanic/Latino 0 (0.0%) 3 (5.8%) 3 (4.8%)
Time from initial diagnosis to randomization, months, median (range) 18.5 (6 to 136) 15.5 (4 to 95) 15.5 (4 to 136)
Time from most recent progression/ relapse to randomization, months, median (range) 3.5 (3 to 5) 5.0 (2 to 16) 4.0 (2 to 16)
Disease diagnosis, n (%)
Diffuse large B cell lymphoma 4 (40.0%) 23 (44.2%) 27 (43.5%)
T cell lymphoma 3 (30.0%) 4 (7.7%) 7 (11.3%)
Mantle cell lymphoma 2 (20.0%) 7 (13.5%) 9 (14.5%)
Follicular lymphoma 0 (0.0%) 7 (13.5%) 7 (11.3%)
Other 1 (10.0%) 11 (21.1%) 12 (19.4%)
Disease stage at initial diagnosis, n (%)
I 1 (10.0%) 3 (5.8%) 4 (6.5%)
II 1 (10.0%) 12 (23.1%) 13 (21.0%)
III 1 (10.0%) 17 (32.7%) 18 (29.0%)
IV 7 (70.0%) 19 (36.5%) 26 (41.9%)
Missing 0 (0.0%) 1 (1.9%) 1 (1.6%)
Disease stage before mobilization, n (%)
I 0 (0.0%) 6 (11.5%) 6 (9.7%)
II 1 (10.0%) 9 (17.3%) 10 (16.1%)
III 2 (20.0%) 12 (23.1%) 14 (22.6%)
IV 5 (50.0%) 17 (32.7%) 22 (35.5%)
Missing 2 (20.0%) 8 (15.4%) 10 (16.1%)
Remission status before mobilization, n (%)
First complete remission 3 (30.0%) 9 (17.3%) 12 (19.4%)
First partial remission 3 (30.0%) 5 (9.6 %) 8 (12.9%)
Second complete remission 1 (10.0%) 17 (32.7%) 18 (29.0%)
Second partial remission 3 (30.0%) 21 (40.4%) 24 (38.7%)
Received previous radiotherapy, n (%) 5 (50.0%) 13 (25.0%) 18 (29.0%)
Biol Blood Marrow Transplant 15:1578-1586, 2009 1581Plerixafor and Hematopoietic Stem Cell Mobilization in NHLpatients, 62 (10 in the plerixafor group and 52 in the
placebo group) elected to receive treatment with pler-
ixafor plus G-CSF in the rescue protocol. Patient dis-
position is shown in Figure 2. The remaining
6 patients achieved yields of 0.31, 0.41, 0.59, 1.42,
1.74, and 2.45 106 CD341 cells/kg in the first mobi-
lization but chose not to enter the rescue protocol.
The CD341 cell yields achieved in the first mobiliza-
tion for these 6 patients were similar to those achieved
by the 62 patients who entered the rescue procedure
(median, 0.78  106 CD341 cells/kg; range, 0.03-
2.33  106 CD341 cells/kg).
Of the 62 patients who failed the initial mobiliza-
tion and entered the rescue protocol, 6 (1 from the
plerixafor arm and 5 from the placebo arm) either
missed a dose of G-CSF or suffered a G-CSF adminis-
tration error during the first mobilization. The demo-
graphic and baseline characteristics of the patients who
entered the rescue protocol were similar to those of the
overall study population (Table 1). Fifty-two of the 62
patients proceeded to autologous stem cell transplan-
tation (described below). All 52 patients completed
100 days posttransplantation follow-up, 46 of the 52
patients (88.5%) completed a 6-month follow-up,
and 44 of the 52 patients (84.6%) completed a 12-
month follow-up.Efficacy
Mobilization
Thirty-seven of the 62 patients in the rescue proto-
col (59.7%) achieved cumulative yields of $2  106
CD341 cells/kg in 4 or fewer days of apheresis, includ-
ing 4 of 10 (40.0%) previously treated in the plerixafor
group and 33 of 52 (63.5%) previously treated in the
placebo group (Table 2). The between-group differ-
ence with respect to the proportion of responders dur-
ing rescue was not statistically significant (P 5 .11,
Fisher’s exact test). In addition, 7 of the 62 patients
(11.3%), all of whom were previously treated in the
placebo group, achieved $5  106 cells/kg in 4 or
fewer days of apheresis. The overall median cell yield
obtained during rescue mobilization with plerixafor
was higher than that obtained in the same patients in
the first mobilization (2.4  106 vs 0.78  106
CD341 cells/kg). The greatest increase was observed
in those patients who were first mobilized in the pla-
cebo group (median, 2.9  106 CD341 cells/kg).
The CD341 cell yield by apheresis day for pa-
tients in the rescue protocol is depicted in Figure 3.
The majority of CD341 cells were collected during
the first and second days of apheresis during the
rescue procedure.
Table 2. Mobilization and Transplantation Outcomes
Plerixafor (n510) Placebo (n552) Total (n562)
Number of CD34+ cells collected in first mobilization 106 /kg, median (range) 1.1 (0.03 to 1.9) 0.78 (0.06 to 2.3) 0.78 (0.03 to 2.3)*
Number of CD34+ cells collected in rescue mobilization 106 /kg, median (range) 1.3 (0.01 to 3.4) 2.9 (0.16 to 7.3) 2.4 (0.01 to 7.3)
Number of aphereses in rescue mobilization, median (range) 4 (1 to 4) 3 (1 to 4) 3 (1 to 4)
Number of patients achieving $2  106 CD34+ cells/kg in 4 or fewer days of apheresis 4 (40.0%) 33 (63.5%) 37 (59.7%)
Number of patients achieving $5  106 CD34+ cells/kg in 4 or fewer days of apheresis† 0 (0.0%) 7 (13.5%)* 7 (11.3%)
Number of CD34+ cells transplanted 106 /kg, median (range)‡,¶ 3.1 (1.1 to 4.3) 3.8 (1.2 to 10.5) 3.8 (1.1 to 10.5)
Number of patients proceeding to transplantation§ 6 (60.0%) 46 (88.75%) 52 (83.9%)
Median days to neutrophil engraftment 10 11 11
Median days to platelet engraftment 22 20 20
*Three patients entered the rescue procedure based on a CD34+ count of <2  106 cells/kg as determined by the local laboratory. Calculations per-
formed later by the central laboratory determined the CD34+ counts to be $2  106 cells/kg, and these results are presented here.
†The 7 patients who collected $5  106 CD34+ cells/kg compose a subset of patients who collected $2  106 CD34+ cells/kg.
‡Transplantation data were not available for 10 patients.
§Some patients in both groups received mixed cells for transplantation.
¶Six patients received <2  106 CD34+ cells/kg, 1 patient through bone marrow harvest.
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PB CD341 cell counts were available for a total of
48 patients, including 9 patients previously treated in
the plerixafor group and 39 previously treated in the
placebo group. The remaining 14 patients were miss-
ing a least one PB CD341 cell count and thus were ex-
cluded from the analysis. The median number of PB
CD341 cells on day 4 (before the first dose of plerixa-
for in the rescue protocol) was 2.7 cells/mL (range, 0.0-
15.6 cells/mL) in the patients previously treated in the
plerixafor group and 1.5 cells/mL (range, 0.0-70.2
cells/mL) in those previously treated in the placebo
group (P5 .176). On day 5, 10-11 hours after the first
plerixafor dose, the median number of PBCD341 cells0
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Figure 3. CD341 cell yiewas 4.9 cells/mL (range, 0.0-26.3 cells/mL) in the pa-
tients previously treated in the plerixafor group and
11.0 cells/mL (range, 0.0-93.0 cells/mL) in those previ-
ously treated in the placebo group (P5 .263). The me-
dian fold increase over the 24-hour period from day 4
to day 5 associated with the first dose of plerixafor was
1.6 (range, 0.4 to 2.0) in patients previously treated in
the plerixafor group and 6.7 (range, 0.3 to 23.0) in
those previously treated in the placebo group (P \
.001).
Transplantation and engraftment
Of the 62 rescue patients, 52 (84%) proceeded to
transplantation. Generally, the transplanted cells3rd (N=43) 4th (N=31)
ol Apheresis Day 
, boxes represent the 25%-75% range,
lds by apheresis day.
Table 3. Graft Durability Based on Laboratory Criteria
Time Point
Posttransplantaton
Patients With a
Durable Graft
Platelet
Count $150  109/L
Platelet
Count $100  109/L
Neutrophil
Count $1.5  109/L
Neutrophil
Count $1.0  109/L
100 days 48/52 (92.3%) 21/47 (44.7%) 32/47 (68.1%) 38/46 (82.6%) 39/46 (84.8%)
6 months 43/46 (93.5%) 21/37 (56.8%) 28/37 (75.7%) 34/37 (91.9%) 37/37 (100.0%)
12 months 40/44 (90.9%) 14/18 (77.8%) 16/18 (88.9%) 18/18 (100.0%) 18/18 (100.0%)
Percentages are based on the overall number of patients with available data at each time point.
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mobilizations. Nine patients received cells from the
rescue procedure only. Five patients underwent fur-
ther mobilization with G-CSF alone and/or BM har-
vest poststudy and received cells combined from the
first and rescue mobilizations, plus cells from these
subsequent collections. For these 5 patients,
the cumulative on-study collections were 1.19, 1.28,
1.49, 1.92, and 1.94 106 CD341 cells/kg. Six patients
received a transplant containing \2  106 CD341
cells/kg (minimum, 1.14  106 CD341 cells /kg). Of
the 10 patients who did not undergo transplantation,
6 (2 previously treated in the plerixafor group and 4
previously treated in the placebo group) failed to mo-
bilize sufficient cells to proceed to transplantation, and
the remaining 4 (2 previously treated in the plerixafor
group and 2 previously treated in the placebo group)
withdrew from the study before completing mobiliza-
tion and HSC collection (1 elective withdrawal, 2
deaths because of progressive disease, and 1 ‘‘other;’’
details not provided).
Themedian time to neutrophil engraftment was 11
days in all patients (Table 2). Fifty of the 52 patients
(96.2%) achieved successful platelet engraftment, with
a median time to platelet engraftment of 20 days. Of
the 2 patients who did not achieve platelet engraftment,
1 patient achieved a total yield of 1.25  106 CD341
cells/kg during the rescue procedure and 0.06  106
CD341 cells/kg during the initial phase 3 study and re-
ceived a total of 2.81  106 CD341 cells/kg, combined
from both collections plus cells from off-study collec-
tion. This patient died from multisystem organ failure
11 days after transplantation. The second patient expe-
rienced a delay in platelet recovery as a consequence of
a severe infection. This patient received cells combined
from rescue and first collections (5.78  106 CD341
and 0.73  106 CD341 cells/kg, respectively). After
transplantation, the patientwas admitted to the hospital
for a small bowel obstruction and subsequently experi-
enced a septic episode. The patient underwent surgery
to resolve the bowel obstruction and received antibiotic
treatment for Clostridium difficile colitis. This patient
survived and met platelet engraftment criteria approxi-
mately 10 months after transplantation.
Graft durability
Graft durability was assessed at 100 days, 6months,
and 12 months posttransplantation. The proportion of
patients who maintained a durable graft based onlaboratory criteria and achieved threshold platelet
and neutrophil counts is summarized in Table 3. Based
on laboratory criteria alone, 9 patients did not meet the
hematologic criteria for graft durability at 1 or more
time points. At 100 days posttransplantation, 48 of
the 52 patients had durable grafts, 3 patients did not
meet the hematologic criteria for graft durability,
and 1 patient died before the visit. At 6 months post-
transplantation, 46 patients were evaluable, and 3 pa-
tients did not meet the criteria for graft durability. At
12months posttransplantation, 44 patients were evalu-
able, and 4 patients did not meet the criteria for graft
durability. Collectively, of the 9 patients who did not
meet the criteria for graft durability, 3 died before lab-
oratory analysis and 6 were considered to have durable
grafts based on investigator assessment at last available
follow-up or before death from disease progression.
Based on a combination of laboratory and clinical cri-
teria and investigator evaluation, no patient was con-
sidered to have graft failure.
Patient survival
At the last recorded follow-up (52 patients evalu-
ated at 100 days, 46 patients evaluated at 6 months,
and 44 patients evaluated at 12 months posttransplan-
tation), 53 of the 62 rescue patients (85.5%) were alive.
Nine rescue patients died (2 previously treated in the
plerixafor group and 7 previously treated in the pla-
cebo group). Two deaths, 1 from each treatment
group, occurred following mobilization and HSC col-
lection, with the patients not proceeding to transplan-
tation. Both of these deaths resulted from disease
progression. The remaining 7 deaths occurred after
transplantation (range, 2-45 weeks posttransplanta-
tion) and were due to disease progression in 1 patient,
respiratory failure secondary to disease progression in
1 patient, relapse in 2 patients, multiple infections and
septic shock in 1 patient (who was considered to have
a durable graft before these events), and multisystem
organ failure in 2 patients. The 1-year posttransplanta-
tion survival for the patients entered on rescue was
similar to that in the entire phase 3 group.
Safety
Adverse events
Overall, the safety findings for the patients treated
in the rescue protocol were consistent with those of the
overall phase 3 study population. During the period of
Table 4. AEs Experienced by$10% of Patients during Mobi-
lization, Treatment, and Apheresis
AE, n (%) Plerixafor (n 5 10) Placebo (n 5 52) Total (n 5 62)
Any AE 10 (100.0) 49 (94.2) 59 (95.2)
Diarrhea 6 (60.0) 21 (40.4) 27 (43.5)
Injection site erythema 4 (40.0) 17 (32.7) 21 (33.9)
Bone pain 2 (20.0) 16 (30.8) 18 (29.0)
Nausea 2 (20.0) 16 (30.8) 18 (29.0)
Paresthesia 4 (40.0) 11 (21.2) 15 (24.2)
Headache 1 (10.0) 13 (25.0) 14 (22.6)
Hypokalemia 1 (10.0) 10 (19.2) 11 (17.7)
Vomiting 1 (10.0) 8 (15.4) 9 (14.5)
Arthralgia 1 (10.0) 7 (13.5) 8 (12.9)
Back pain 3 (30.0) 4 (7.7) 7 (11.3)
Fatigue 0 (0.0) 7 (13.5) 7 (11.3)
Injection site pruritus 2 (20.0) 5 (9.6) 7 (11.3)
Paresthesia oral 1 (10.0) 6 (11.5) 7 (11.3)
Hypomagnesemia 1 (10.0) 5 (9.6) 6 (9.7)*
Muscle spasms 1 (10.0) 5 (9.6) 6 (9.7)*
Pain 1 (10.0) 5 (9.6) 6 (9.7)*
AE indicates adverse events.
*Rounded to 10% for the purpose of this table.
1584 Biol Blood Marrow Transplant 15:1578-1586, 2009I. N. Micallef et al.treatment, mobilization, and apheresis, 59 of the 62
rescue patients (95.2%) experienced at least 1 AE con-
sidered to be related to the study treatment (Table 4).
The most common drug-related AEs occurring during
this period, in descending order, were diarrhea
(43.5%), injection site erythema (33.9%), bone pain
(29.0%), nausea (29.0%), headache (29.0%), and par-
esthesias (24.2%). Most of the AEs related to the study
treatment were mild or moderate. There were no life-
threatening AEs.
Ten patients received 2 treatment cycles of plerix-
afor (median, 7 doses; range, 3-8 doses), with the first
treatment cycle as part of the blinded study period and
the second treatment cycle as part of the rescue proto-
col. The AE profiles for these patients were similar for
each treatment and included injection site reactions,
gastrointestinal effects, paresthesias, and headache. Al-
most all of these AEs were mild, and none was severe.
No increased incidence or severity of these AEs was
apparent during the second plerixafor treatment cycle.
Serious adverse events
A total of 44 SAEs were experienced by 22 of the 62
patients (35.5%). The most common SAEs—atrial
fibrillation (3 patients), mucositis (2 patients), and hy-
potension (2 patients)—occurred after mobilization,
following the myeloablative chemotherapy. None of
these SAEs was related to the study treatment.
Adverse events leading to discontinuation of
study treatment or study withdrawal
Four patients did not complete the rescue proce-
dure because of AEs or withdrawal from the study.
One patient received 4 doses of plerixafor during the
first mobilization and then entered the rescue proto-
col. This patient experienced bone pain, headache,nausea, and vomiting, considered to be related to the
study treatment; he discontinued plerixafor treatment
after 1 dose in the rescue protocol, but subsequently
proceeded to transplantation and completed the study.
One patient experienced progression of NHL and
sepsis considered to be unrelated to the study treat-
ment and died before completion of mobilization
and apheresis. Two other patients withdrew from the
study during the mobilization period, but not because
of AEs (1 elective withdrawal and 1 ‘‘other’’).DISCUSSION
Our data demonstrate that of the 62 patients who
entered the rescue protocol, 52 (83.9%) could proceed
to transplantation after remobilization with plerixafor
plus G-CSF. Patients who were initially mobilized
with G-CSF alone in the placebo group of the phase
3 study had the best response to remobilization with
plerixafor plus G-CSF: 4 of 10 (40.0%) in the plerixa-
for group and 33 of 52 (63.5%) in the placebo group
achieved $2  106 CD341 cells/kg in 4 or fewer
days of apheresis. Patients previously treated in the
placebo group (7/52 13.5%) achieved cumulative
yields of$5 106 CD341 cells/kg. This was likely be-
cause of the fold increase in PB CD341 cell count,
which was not significant in the patients previously
treated in the plerixafor group but was a mean of
7.9-fold in those previously treated in the placebo
group. Six of 10 patients (60.0%) previously treated
in the plerixafor group and 46 of 52 patients
(88.75%) previously treated in the placebo group pro-
ceeded to transplantation, indicating that mobilization
with plerixafor plus G-CSF increased the number of
patients who achieved sufficient cell collections to pro-
ceed to transplantation, both as an initial therapy and
during remobilization.
Of note, the baseline characteristics were similar in
the patients in the rescue protocol and the overall
phase 3 study population, suggesting that demograph-
ics, time from disease diagnosis, time from disease
progression, disease stage, remission status, prior sur-
gery, prior chemotherapy, and prior radiotherapy may
not accurately predict mobilization failure in this pop-
ulation. Themajority of patients (45/52; 86.5%)mobi-
lized with G-CSF alone in the placebo group achieved
a greater median yield of CD341 cells/kg during res-
cue mobilization (2.9  106 cells/kg) than in the first
mobilization (0.78 106 cells/kg). Thus, the contribu-
tion to the pool of cells available for transplantation
was generally greater from mobilization with plerixa-
for plus G-CSF than from mobilization with G-CSF
alone. Forty percent of the patients who failed their
first mobilization in the plerixafor group achieved suf-
ficient cell yields for transplantation following mobili-
zation on the rescue protocol. These patients received
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first mobilization and the rescue protocol. These re-
sults illustrate that remobilization with plerixafor
plus G-CSF still had some benefit when the original
mobilization regimen included plerixafor, and that
a 1-week recovery period between first and second
mobilizations seemed to be effective for subsequent
collections.
The majority of patients underwent successful
transplantation following the rescue procedure. Nine
of the 52 patients (17.3%) received cells from the res-
cue procedure only; the remaining patients received
cells combined from the first and rescue mobilizations,
plus cells from subsequent off-study collections in 5
cases. Despite the various cell sources, time to engraft-
ment and graft durability were not markedly different
between the patients in the rescue protocol and the
overall study population. Transplantation with cells
collected during the rescue protocol resulted in com-
parable rates of engraftment and graft durability as
transplantation using cells from a single mobilization.
This indicates that the quality of cells collected in the
rescue protocol was similar to that of cells collected in
the parent phase 3 study. In addition, hematologic data
(ie, neutrophil counts, platelet counts, and hemoglo-
bin) were similar between the rescue patients and
patients in the parent phase 3 study at 100 days, 6
months, and 12 months posttransplantation. Engraft-
ment of cells collected during the rescue procedure
was timely and durable. Neutrophil engraftment was
observed for all patients, and platelet engraftment
was observed for all but 2 patients, both of whom expe-
rienced complications after transplantation.
Previous studies of mobilization with G-CSF
alone in patients with NHL have shown that 50%-
90% achieve sufficient cell collections for transplanta-
tion in the first mobilization [4,14,15]. Remobilization
strategies including high-dose G-CSF, G-CSF plus
GM-CSF, and G-CSF plus chemotherapy produce
success rates of 24%-65%, depending on the defini-
tion of failure and on whether or not the subsequent
mobilizations were pooled [4,8,10,16]. In the pivotal
phase II study, the washout period ranged from 13 to
17 days from the time the first set of mobilizing cyto-
kines was completed until the second set of mobilizing
cytokines was initiated [2]. This interval seemed to be
safe and effective for stem cell mobilization. Lefrere
et al. [16] reported successful remobilization with
high-dose G-CSF after a 7-day rest period in patients
who failed chemomobilization. Thus, in the present
study, a 7-day period was chosen based on a combina-
tion of clinical experience in earlier plerixafor studies,
published literature, and the desire to keep the overall
treatment period as short as possible.
In this study, we found a remobilization success
rate of 63.5% in a median of 3 aphereses using plerix-
afor plus G-CSF following failed mobilization withG-CSF alone. This finding indicates that remobiliza-
tion with plerixafor plus G-CSF is an efficient and
effective method of collecting HSCs in patients who
previously failed mobilization. These results are simi-
lar to those from previous studies of compassionate use
of plerixafor, in which a diverse patient population (in-
cluding those with NHL) was remobilized after failed
mobilization with conventional cytokine and/or che-
motherapy [16,17]. Entry into the compassionate use
protocol (CUP) was limited to patients who had previ-
ously failed to proceed from mobilization to apheresis
because of a low peripheral blood CD341 cell count
(usually#10 cells/mL) or because of an initial apheresis
yield below the minimum amount for transplantation,
usually 2  106 CD341 cells/kg. In almost all cases,
this assessment was made based on the first apheresis
after mobilization. The median time between mobili-
zation failure and treatment in the CUP was approxi-
mately 1 month. Some 60% of patients with NHL
achieved a cumulative yield of $2  106 CD341
cells/kg in the CUP from a median of 3 aphereses
[16]. The results of remobilization studies, including
the CUP study, are typically confounded by such fac-
tors as the lack of a well-defined patient population
with any strict inclusion/exclusion criteria and the
lack of a consistent definition of poor mobilization.
But the rescue protocol data presented here permit
evaluation of remobilization in a well-defined popula-
tion of patients with NHL. The rate of successful re-
mobilization with plerixafor plus G-CSF following
failed mobilization with G-CSF alone was 63.5%;
this is consistent with the rate from the CUP study
and superior to most successful remobilization rates
from G-CSF, other cytokines, chemotherapy, and
other investigational agents. In addition, mobilization
of HSCs with plerixafor plus G-CSF carries no unex-
pected safety concerns.
In conclusion, in the phase 3 study, plerixafor plus
G-CSF was shown to be a more effective regimen than
G-CSF alone for initial mobilization in NHL patients.
The rescue protocol demonstrates that remobilization
with plerixafor plusG-CSF also has a benefit for a large
proportion of failed mobilizers.ACKNOWLEDGMENTS
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